Nitric oxide (NO)-donors: the Nicox expertise
Nicox has developed a world-leading position in the therapeutic application of NO-donating compounds, based on a strong research platform which creates New Molecular Entities (NMEs). Our specialized Research Center in Italy has worked on many R&D studies covering various therapy areas such as cardiovascular, inflammation and ophthalmology creating one of the most significant patent portfolios in the area. Nicox’s compounds, known as NO-donors, are designed to donate nitric oxide with a sustained pharmacological effect at tissue level aiming at avoiding the drawbacks related to the rapid burst of nitric oxide associated with traditional nitrates.
Focus on ocular disorders
In line with Nicox’s strategic positioning in the ophthalmic space, the research platform is now focused on ocular diseases where nitric oxide (NO) has been shown to play an important role. A specialized team in Nicox’s Italian research subsidiary, Nicox Srl, is pursuing targeted projects in collaboration with external research centers. This will enable Nicox to enhance its knowledge of the role and potential of nitric oxide (NO) in the eye and to leverage its long-standing expertise in the therapeutic application of NO-donating compounds. Many studies show that nitric oxide is involved in the eye’s physiology and pathophysiology. The phase 3 results for latanoprostene bunod confirmed the strong potential of our NO-donating proprietary research platform in ophtalmology.